Evidence map›Paper›PMID 34059711›Full record

ArticleScientific reports2021

Fluorescent base analogues in gapmers enable stealth labeling of antisense oligonucleotide therapeutics.

Jesper R Nilsson, Tom Baladi, Audrey Gallud, Dženita Baždarević, Malin Lemurell, Elin K Esbjörner, L Marcus Wilhelmsson, Anders Dahlén

Abstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jesper R NilssonDepartment of Chemistry and Chemical Engineering, Chalmers University of Technology, 412 96, Gothenburg, Sweden.
Tom BaladiDepartment of Chemistry and Chemical Engineering, Chalmers University of Technology, 412 96, Gothenburg, Sweden.
Audrey GalludDepartment of Biology and Biological Engineering, Chalmers University of Technology, 41296, Gothenburg, Sweden.
Dženita BaždarevićBioscience, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Malin LemurellMedicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Elin K EsbjörnerDepartment of Biology and Biological Engineering, Chalmers University of Technology, 41296, Gothenburg, Sweden.
L Marcus WilhelmssonDepartment of Chemistry and Chemical Engineering, Chalmers University of Technology, 412 96, Gothenburg, Sweden.
Anders DahlénOligonucleotide Discovery, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. anders.dahlen@astrazeneca.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To expand the antisense oligonucleotide (ASO) fluorescence labeling toolbox beyond covalent conjugation of external dyes (e.g. ATTO-, Alexa Fluor-, or cyanine dyes), we herein explore fluorescent base analogues (FBAs) as a novel approach to endow fluorescent properties to ASOs. Both cytosine and adenine analogues (tC, tC

Indexed as

Cell SurvivalFlow CytometryFluorescent DyesHEK293 CellsHumansMicroscopy, FluorescenceNucleic Acid ConformationOligonucleotides, AntisenseReal-Time Polymerase Chain ReactionReverse TranscriptionSpectrophotometry, UltravioletFluorescent DyesOligonucleotides, Antisense

Identifiers

PMID34059711
PMCPMC8166847

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.